The U.S. Food and Drug Administration this week approved Gilead Sciences’ twice-a-year shot, lenacapvir, to prevent HIV, Gilead announced on Wednesday, June 18. It is the first and only long-acting ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

Newly FDA-approved HIV prevention drug, Yeztugo, offers protection for six months—yet the need for a vaccine remains, say ...

This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthrou ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...